Top

Current Osteoporosis Reports

Published in:

01-08-2019 | Fracture Healing | Skeletal Biology and Regulation (M Forwood and A Robling, Section Editors)

CaMKK2 Signaling in Metabolism and Skeletal Disease: a New Axis with Therapeutic Potential

Authors: Justin N. Williams, Uma Sankar

Published in: Current Osteoporosis Reports | Issue 4/2019

Abstract

Purpose of Review

Age and metabolic disorders result in the accumulation of advanced glycation endproducts (AGEs), oxidative stress, and inflammation, which cumulatively cause a decline in skeletal health. Bone becomes increasingly vulnerable to fractures and its regenerative capacity diminishes under such conditions. With a rapidly aging population in the USA and the global increase in diabetes, efficacious, multi-dimensional therapies that can treat or prevent skeletal diseases associated with metabolic dysfunction and inflammatory disorders are acutely needed.

Recent Findings

Ca²⁺/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is a key regulator of nutrient intake, glucose metabolism, insulin production, and adipogenesis. Recent studies suggest a pivotal role for CaMKK2 in bone metabolism, fracture healing, and inflammation.

Summary

Aside from rekindling previous concepts of CaMKK2 as a potent regulator of whole-body energy homeostasis, this review emphasizes CaMKK2 as a potential therapeutic target to treat skeletal diseases that underlie metabolic conditions and inflammation.

Yelin EH, Cisternas M. Annual all-cause and incremental direct costs for all musculoskeletal diseases in current and 2014 dollars, United States 1996-2014. The burden of musculoskeletal diseases in the united States 2017.

Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or Zoledronic acid in postmenopausal women with osteoporosis previously treated with Oral bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163–70. https://doi.org/10.1210/jc.2016-1801.CrossRefPubMedPubMedCentral

Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. P T. 2018;43(2):92–104.PubMedPubMedCentral

Jin A, Cobb J, Hansen U, Bhattacharya R, Reinhard C, Vo N, et al. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res. 2017;6(10):602–9. https://doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1.CrossRefPubMedPubMedCentral

Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial. Bone. 2018;120:137–40. https://doi.org/10.1016/j.bone.2018.10.015.CrossRefPubMed

Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503–11. https://doi.org/10.1002/jbmr.238.CrossRefPubMed

Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, et al. FRAME study: the Foundation effect of building bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to Denosumab. J Bone Miner Res. 2018;33(7):1219–26. https://doi.org/10.1002/jbmr.3427.CrossRefPubMed

Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395–402. https://doi.org/10.1001/archinternmed.2009.214.CrossRefPubMed

Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251–62. https://doi.org/10.1038/nrm3311.CrossRefPubMedPubMedCentral

10.

McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14–20. https://doi.org/10.1016/j.clindermatol.2017.09.004.CrossRefPubMed

11.

Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27(1):219–28. https://doi.org/10.1007/s00198-015-3279-7.CrossRefPubMed

12.

Miranda C, Giner M, Montoya MJ, Vazquez MA, Miranda MJ, Perez-Cano R. Influence of high glucose and advanced glycation end-products (ages) levels in human osteoblast-like cells gene expression. BMC Musculoskelet Disord. 2016;17:377. https://doi.org/10.1186/s12891-016-1228-z.CrossRefPubMedPubMedCentral

13.

•• Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411–29. https://doi.org/10.1016/j.redox.2013.12.016. The study uggests that the skeleton is capable of regulating systemic glucose homeostasis. CrossRefPubMedPubMedCentral

14.

Dirckx N, Tower RJ, Mercken EM, Vangoitsenhoven R, Moreau-Triby C, Breugelmans T, et al. Vhl deletion in osteoblasts boosts cellular glycolysis and improves global glucose metabolism. J Clin Invest. 2018;128(3):1087–105. https://doi.org/10.1172/JCI97794.CrossRefPubMedPubMedCentral

15.

Carafoli E. Calcium signaling: a tale for all seasons. Proc Natl Acad Sci U S A. 2002;99(3):1115–22. https://doi.org/10.1073/pnas.032427999.CrossRefPubMedPubMedCentral

16.

Clapham DE. Calcium signaling. Cell. 2007;131(6):1047–58. https://doi.org/10.1016/j.cell.2007.11.028.CrossRefPubMed

17.

Marcelo KL, Means AR, York B. The ca(2+)/calmodulin/CaMKK2 Axis: Nature's metabolic CaMshaft. Trends Endocrinol Metab. 2016;27(10):706–18. https://doi.org/10.1016/j.tem.2016.06.001.CrossRefPubMedPubMedCentral

18.

Racioppi L, Means AR. Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology. J Biol Chem. 2012;287(38):31658–65. https://doi.org/10.1074/jbc.R112.356485.CrossRefPubMedPubMedCentral

19.

Green MF, Scott JW, Steel R, Oakhill JS, Kemp BE, Means AR. Ca2+/calmodulin-dependent protein kinase kinase beta is regulated by multisite phosphorylation. J Biol Chem. 2011;286(32):28066–79. https://doi.org/10.1074/jbc.M111.251504.CrossRefPubMedPubMedCentral

20.

Tokumitsu H, Hatano N, Fujimoto T, Yurimoto S, Kobayashi R. Generation of autonomous activity of ca(2+)/calmodulin-dependent protein kinase kinase beta by autophosphorylation. Biochemistry. 2011;50(38):8193–201. https://doi.org/10.1021/bi201005g.CrossRefPubMed

21.

Green MF, Anderson KA, Means AR. Characterization of the CaMKKbeta-AMPK signaling complex. Cell Signal. 2011;23(12):2005–12. https://doi.org/10.1016/j.cellsig.2011.07.014.CrossRefPubMedPubMedCentral

22.

Dadwal UC, Chang ES, Sankar U. Androgen receptor-CaMKK2 Axis in prostate Cancer and bone microenvironment. Front Endocrinol (Lausanne). 2018;9:335. https://doi.org/10.3389/fendo.2018.00335.CrossRef

23.

Lin F, Marcelo KL, Rajapakshe K, Coarfa C, Dean A, Wilganowski N, et al. The camKK2/camKIV relay is an essential regulator of hepatic cancer. Hepatology. 2015;62(2):505–20. https://doi.org/10.1002/hep.27832.CrossRefPubMed

24.

Anderson KA, Ribar TJ, Lin F, Noeldner PK, Green MF, Muehlbauer MJ, et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 2008;7(5):377–88. https://doi.org/10.1016/j.cmet.2008.02.011.CrossRefPubMed

25.

Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177–97. https://doi.org/10.1002/cphy.c130024.CrossRefPubMedPubMedCentral

26.

Anderson KA, Lin F, Ribar TJ, Stevens RD, Muehlbauer MJ, Newgard CB, et al. Deletion of CaMKK2 from the liver lowers blood glucose and improves whole-body glucose tolerance in the mouse. Mol Endocrinol. 2012;26(2):281–91. https://doi.org/10.1210/me.2011-1299.CrossRefPubMedPubMedCentral

27.

York B, Li F, Lin F, Marcelo KL, Mao J, Dean A, et al. Pharmacological inhibition of CaMKK2 with the selective antagonist STO-609 regresses NAFLD. Sci Rep. 2017;7(1):11793. https://doi.org/10.1038/s41598-017-12139-3.CrossRefPubMedPubMedCentral

28.

Marcelo KL, Ribar T, Means CR, Tsimelzon A, Stevens RD, Ilkayeva O, et al. Research resource: roles for calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in systems metabolism. Mol Endocrinol. 2016;30(5):557–72. https://doi.org/10.1210/me.2016-1021.CrossRefPubMedPubMedCentral

29.

Tokumitsu H, Inuzuka H, Ishikawa Y, Ikeda M, Saji I, Kobayashi R. STO-609, a specific inhibitor of the ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002;277(18):15813–8. https://doi.org/10.1074/jbc.M201075200.CrossRefPubMed

30.

Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005;2(1):9–19. https://doi.org/10.1016/j.cmet.2005.05.009.CrossRefPubMed

31.

Lin F, Ribar TJ, Means AR. The Ca2+/calmodulin-dependent protein kinase kinase, CaMKK2, inhibits preadipocyte differentiation. Endocrinology. 2011;152(10):3668–79. https://doi.org/10.1210/en.2011-1107.CrossRefPubMedPubMedCentral

32.

Pritchard ZJ, Cary RL, Yang C, Novack DV, Voor MJ, Sankar U. Inhibition of CaMKK2 reverses age-associated decline in bone mass. Bone. 2015;75:120–7. https://doi.org/10.1016/j.bone.2015.01.021.CrossRefPubMedPubMedCentral

33.

Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–4. https://doi.org/10.1038/nm.2452.CrossRefPubMed

34.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889–901.CrossRefPubMed

35.

Cary RL, Waddell S, Racioppi L, Long F, Novack DV, Voor MJ, et al. Inhibition of ca(2)(+)/calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation. J Bone Miner Res. 2013;28(7):1599–610. https://doi.org/10.1002/jbmr.1890.CrossRefPubMed

36.

American Diabetes A. Economic costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–28. https://doi.org/10.2337/dci18-0007.CrossRef

37.

Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–91. https://doi.org/10.1001/jama.2016.6458.CrossRefPubMed

38.

Maimoun L, Mura T, Leprieur E, Avignon A, Mariano-Goulart D, Sultan A. Impact of obesity on bone mass throughout adult life: influence of gender and severity of obesity. Bone. 2016;90:23–30. https://doi.org/10.1016/j.bone.2015.11.020.CrossRefPubMed

39.

King LK, March L, Anandacoomarasamy A. Obesity & osteoarthritis. Indian J Med Res. 2013;138:185–93.PubMedPubMedCentral

40.

Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96(6):1654–63. https://doi.org/10.1210/jc.2011-0585.CrossRefPubMedPubMedCentral

41.

Son M, Chung WJ, Oh S, Ahn H, Choi CH, Hong S, et al. Age dependent accumulation patterns of advanced glycation end product receptor (RAGE) ligands and binding intensities between RAGE and its ligands differ in the liver, kidney, and skeletal muscle. Immun Ageing. 2017;14:12. https://doi.org/10.1186/s12979-017-0095-2.CrossRefPubMedPubMedCentral

42.

Gautieri A, Passini FS, Silvan U, Guizar-Sicairos M, Carimati G, Volpi P, et al. Advanced glycation end-products: mechanics of aged collagen from molecule to tissue. Matrix Biol. 2017;59:95–108. https://doi.org/10.1016/j.matbio.2016.09.001.CrossRefPubMed

43.

Cannizzaro L, Rossoni G, Savi F, Altomare A, Marinello C, Saethang T, et al. Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARgamma activation in high fructose diet-induced metabolic syndrome. Nutr Metab (Lond). 2017;14:5. https://doi.org/10.1186/s12986-016-0149-z.CrossRef

44.

Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun. 2015;461(2):193–9. https://doi.org/10.1016/j.bbrc.2015.02.091.CrossRefPubMed

45.

Tanaka K, Yamaguchi T, Kaji H, Kanazawa I, Sugimoto T. Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic reticulum stress. Biochem Biophys Res Commun. 2013;438(3):463–7. https://doi.org/10.1016/j.bbrc.2013.07.126.CrossRefPubMed

46.

Davidson MB. Thiazolidinediones. N Engl J Med. 2005;352(2):205–7; author reply -7. https://doi.org/10.1056/NEJM200501133520222.CrossRefPubMed

47.

Broulik PD, Sefc L, Haluzik M. Effect of PPAR-gamma agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice. Folia Biol (Praha). 2011;57(4):133–8.

48.

Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32–9. https://doi.org/10.1503/cmaj.080486.CrossRefPubMedPubMedCentral

49.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355–69. https://doi.org/10.1172/JCI40671.CrossRefPubMedPubMedCentral

50.

Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253–70. https://doi.org/10.1042/CS20110386.CrossRef

51.

Li Y, Su J, Sun W, Cai L, Deng Z. AMP-activated protein kinase stimulates osteoblast differentiation and mineralization through autophagy induction. Int J Mol Med. 2018;41(5):2535–44. https://doi.org/10.3892/ijmm.2018.3498.CrossRefPubMedPubMedCentral

52.

Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011;112(10):2902–9. https://doi.org/10.1002/jcb.23206.CrossRefPubMed

53.

McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. World J Diabetes. 2016;7(6):122–33. https://doi.org/10.4239/wjd.v7.i6.122.CrossRefPubMedPubMedCentral

54.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808. https://doi.org/10.1172/JCI19246.CrossRefPubMedPubMedCentral

55.

Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11(3):234–50. https://doi.org/10.1038/nrd3669.CrossRefPubMed

56.

Tsiotra PC, Boutati E, Dimitriadis G, Raptis SA. High insulin and leptin increase resistin and inflammatory cytokine production from human mononuclear cells. Biomed Res Int. 2013;2013:487081. https://doi.org/10.1155/2013/487081.CrossRefPubMed

57.

Hughes FJ, Turner W, Belibasakis G, Martuscelli G. Effects of growth factors and cytokines on osteoblast differentiation. Periodontol. 2006;41:48–72. https://doi.org/10.1111/j.1600-0757.2006.00161.x.CrossRef

58.

Confalone E, D'Alessio G, Furia A. IL-6 induction by TNFalpha and IL-1beta in an osteoblast-like cell line. Int J Biomed Sci. 2010;6(2):135–40.PubMedPubMedCentral

59.

Garcia-Martinez O, De Luna-Bertos E, Ramos-Torrecillas J, Manzano-Moreno FJ, Ruiz C. Repercussions of NSAIDS drugs on bone tissue: the osteoblast. Life Sci. 2015;123:72–7. https://doi.org/10.1016/j.lfs.2015.01.009.CrossRefPubMed

60.

Bhattacharyya T, Levin R, Vrahas MS, Solomon DH. Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum. 2005;53(3):364–7. https://doi.org/10.1002/art.21170.CrossRefPubMed

61.

Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open. 2015;1(1):e000014. https://doi.org/10.1136/rmdopen-2014-000014.CrossRefPubMedPubMedCentral

62.

Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem. 2007;282(33):24120–30. https://doi.org/10.1074/jbc.M611435200.CrossRefPubMed

63.

Racioppi L, Noeldner PK, Lin F, Arvai S, Means AR. Calcium/calmodulin-dependent protein kinase kinase 2 regulates macrophage-mediated inflammatory responses. J Biol Chem. 2012;287(14):11579–91. https://doi.org/10.1074/jbc.M111.336032.CrossRefPubMedPubMedCentral

64.

Shah VN, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. Diabet Med. 2015;32(9):1134–42. https://doi.org/10.1111/dme.12734.CrossRefPubMedPubMedCentral

65.

Hak DJ, Fitzpatrick D, Bishop JA, Marsh JL, Tilp S, Schnettler R, et al. Delayed union and nonunions: epidemiology, clinical issues, and financial aspects. Injury. 2014;45(Suppl 2):S3–7. https://doi.org/10.1016/j.injury.2014.04.002.CrossRefPubMed

66.

Griffin XL. Low intensity pulsed ultrasound for fractures of the tibial shaft. BMJ. 2016;355:i5652. https://doi.org/10.1136/bmj.i5652.CrossRefPubMedPubMedCentral

67.

Kim HS, Nam ST, Mun SH, Lee SK, Kim HW, Park YH, et al. DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation. Nat Commun. 2017;8(1):1519. https://doi.org/10.1038/s41467-017-01527-y.CrossRefPubMedPubMedCentral

68.

Okonkwo UA, DiPietro LA. Diabetes and wound angiogenesis. Int J Mol Sci. 2017;18(7). https://doi.org/10.3390/ijms18071419.

69.

•• Tevlin R, Seo EY, Marecic O, McArdle A, Tong X, Zimdahl B, et al. Pharmacological rescue of diabetic skeletal stem cell niches. Sci Transl Med. 2017;9(372). https://doi.org/10.1126/scitranslmed.aag2809. Demonstrates a potential mechanism for type 2 diabetes to impair the skeletal stem cell response during bone fracture healing.

70.

•• Lin YC, Roffler SR, Yan YT, Yang RB. Disruption of Scube2 Impairs Endochondral Bone Formation. J Bone Miner Res. 2015;30(7):1255–67. https://doi.org/10.1002/jbmr.2451. This study reveals inhibition of CaMKK2 promotes efficient bone fracture healing through modulation of IHH. CrossRefPubMed

71.

Williams JN, Kambrath AV, Patel RB, Kang KS, Mevel E, Li Y, et al. Inhibition of CaMKK2 enhances fracture healing by stimulating Indian hedgehog signaling and accelerating endochondral ossification. J Bone Miner Res. 2018;33(5):930–44. https://doi.org/10.1002/jbmr.3379.CrossRefPubMed

Title: CaMKK2 Signaling in Metabolism and Skeletal Disease: a New Axis with Therapeutic Potential
Authors: Justin N. Williams
Uma Sankar
Publication date: 01-08-2019
Publisher: Springer US
Keywords: Fracture Healing
Insulins
Insulins
Published in: Current Osteoporosis Reports / Issue 4/2019
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-019-00518-w

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

CaMKK2 Signaling in Metabolism and Skeletal Disease: a New Axis with Therapeutic Potential

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2019

Integrins in Osteocyte Biology and Mechanotransduction

Studies on Osteocytes in Their 3D Native Matrix Versus 2D In Vitro Models

Towards a Connectomic Description of the Osteocyte Lacunocanalicular Network in Bone

Contextual Regulation of Skeletal Physiology by Notch Signaling

RNA-seq in Skeletal Biology

Investigating Osteocytic Perilacunar/Canalicular Remodeling